- Home
- ERAS vs BOOT Comparison
ERAS vs BOOT Comparison
Compare ERAS & BOOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | BOOT |
|---|---|---|
| Founded | 2018 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.3B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ERAS | BOOT |
|---|---|---|
| Price | $17.86 | $160.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $12.08 | ★ $223.09 |
| AVG Volume (30 Days) | ★ 5.0M | 741.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.23 | 22.50 |
| EPS | N/A | ★ 5.90 |
| Revenue | N/A | ★ $776,854,000.00 |
| Revenue This Year | N/A | $19.98 |
| Revenue Next Year | N/A | $13.91 |
| P/E Ratio | ★ N/A | $26.44 |
| Revenue Growth | N/A | ★ 14.59 |
| 52 Week Low | $1.06 | $86.17 |
| 52 Week High | $18.20 | $210.25 |
Technical Indicators
Market Signals| Indicator | ERAS | BOOT |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 51.48 |
| Support Level | $1.72 | $133.18 |
| Resistance Level | $18.20 | $205.38 |
| Average True Range (ATR) | 1.30 | 8.02 |
| MACD | 0.01 | 2.59 |
| Stochastic Oscillator | 88.45 | 86.21 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.